Logo for LaunchBio Program: Investor Connect PlusLogo for LaunchBio Program: Investor Connect Plus

A LaunchBio x BIO Partnership

Investor Connect Plus
Online

Perceptive Advisors

Reserved for BIO member companies

Program

In partnership with BIO, Investor Connect Plus is an exclusive, curated investor access program designed for established, investor-ready life sciences companies with validated science, demonstrated maturity, and defined capital strategies.


Reserved for BIO member companies with clear capital needs and measurable clinical, technical, or commercial progress, Investor Connect Plus facilitates targeted, one-to-one meetings with institutional and strategic investors actively deploying capital across the life sciences ecosystem. The monthly program emphasizes thoughtful matchmaking, preparation, and efficiency, leading to direct, focused conversations aligned around stage, sector, and strategic interest.

This series is reserved for companies that currently maintain an active BIO membership. We consider Late Seed through Series A–F private life sciences companies and mature, private companies with commercial assets in the global market that demonstrate technical and organizational maturity, have defined capital needs and a clear use of proceeds, and maintain active BIO membership. Entrepreneur applications are accepted on a rolling basis and are considered each month based on the investor’s portfolio interests.

Not a BIO member?

BIO membership connects you and your team to the cost savings, partnerships, and policy solutions needed to drive biotech breakthroughs and advance your business. APPLY HERE TO BECOME A MEMBER.

 

Event

Luma Group

Perceptive Advisors is a partner that can support subsequent venture rounds beyond the seed stage. Perceptive Advisor’s team brings decades of deep operational, strategic and investment experience across treatment modalities and therapeutic areas with a proven track record of success. They prioritize our energy and resources to focus on the careful design of each component of a company’s product development and regulatory plan, from preclinical lead identification through clinical proof of concept data. They believe these choices are essential to the success of any program.

 


Applications will be selected based on meeting the following criteria:

Investment Sector

Therapeutics, Medtech / Medical devices, Diagnostics, Digital health / health software, Research tools & platform, Healthcare services

 

Modalities of Interest

Small molecules, Biologics, Protein-based therapeutics, RNA-based therapeutics, Gene therapies, Gene editing technologies, Cell therapies, Regenerative medicine & tissue engineering, Microbiome & engineered living therapies, Radiopharmaceuticals, Oncolytic viruses, Drug-device combinations & advanced delivery platforms, Diagnostics, AI/ML-Enabled

 

More details on LaunchBio’s Investor Connect Plus series here.

Partners